This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Edwards Lifesciences (EW) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
Improvement in Critical Care and Surgical Structural Heart businesses is expected to have contributed to Edwards Lifesciences' (EW) third-quarter results.
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Q3 Release
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific's (BSX) Ranger DCB Trial Outcome Favorable
by Zacks Equity Research
Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth across the majority of its GBUs as well as in domestic revenues in fiscal 2022 Q1.
The Zacks Analyst Blog Highlights: Facebook, AbbVie, 3M, Broadcom and Edwards Lifesciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, AbbVie, 3M, Broadcom and Edwards Lifesciences
Top Analyst Reports for Facebook, AbbVie & 3M
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Facebook, Inc. (FB), AbbVie Inc. (ABBV), and 3M Company (MMM).
Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on strong sales growth across all four product groups in the second quarter and raised 2021 guidance.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Top Research Reports for Costco, Altria & Edwards Lifesciences
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale (COST), Altria Group, Inc. (MO), and Edwards Lifesciences (EW).
3 Medical Instruments Stocks Countering Industry Headwinds
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on base business recovery. ISRG, IDXX and ALC are set to gain the most. However, falling demand for COVID-19 tests might disrupt the trend.
Hill-Rom (HRC) Q3 Earnings Top Estimates, 2021 Guidance Up
by Zacks Equity Research
Hill-Rom (HRC) reports better-than-expected revenues for third-quarter fiscal 2021 with strong segmental performance driving the top line.
Edwards Lifesciences (EW) Beats on Q2 Earnings, Margins Up
by Zacks Equity Research
Strong sales growth across all four products along with steady improvement in surgical procedure volumes during the second quarter drove Edwards Lifesciences' (EW) revenues.
Edwards Lifesciences (EW) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 16.36% and 7.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Edwards Lifesciences (EW) Ahead of Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in Store for Edwards Lifesciences (EW) Q2 Earnings?
by Zacks Equity Research
Continued adoption of TruWave disposable pressure monitoring devices and progress in transfemoral EVOQUE and SAPIEN M3 platforms are likely to have driven Edwards Lifesciences' (EW) Q2 revenues.
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FTCS
Edwards Lifesciences (EW) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Stock Reports for Exxon Mobil, Texas Instruments & GlaxoSmithKline
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Texas Instruments (TXN), and GlaxoSmithKline (GSK).
Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on
by Debanjana Dey
These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.
Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about Edwards Lifesciences (EW) on its promising Surgical Structural Heart business and bullish 2021 guidance.
Top Stock Reports for Texas Instruments, CSX & Norfolk Southern
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Incorporated (TXN), CSX Corporation (CSX), and Norfolk Southern Corporation (NSC).
Edwards Lifesciences (EW) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Research Reports for JPMorgan, Home Depot & Merck
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase (JPM), The Home Depot (HD), and Merck (MRK).
Edwards Lifesciences (EW) Surges 6.3%: Is This an Indication of Further Gains?
by Zacks Equity Research
Edwards Lifesciences (EW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Edwards Lifesciences (EW) Beats on Q1 Earnings, Margins Down
by Zacks Equity Research
Despite coronavirus-led business challenges, Edwards Lifesciences (EW) witnessed robust segmental performances in Q1.